Ando Masayuki, Imai Kenichirou, Matsunaga Yuuichirou, Ami Katsunori, Ganno Hideaki, Amagasa Hidetoshi, Ohshima Nana, Fukuda Akira, Nagahama Takeshi, Aoki Nobuhiko, Fujiya Keiichi, Arai Kuniyoshi, Tei Shikofumi, Okada Youichi
Dept. of Surgery, Metropolitan Health and Medical Treatment Corporation Toshima Hospital.
Gan To Kagaku Ryoho. 2014 Nov;41(12):1791-3.
A 61-year-old man was diagnosed with rectal cancer with multiple liver metastases in December 2009, and low anterior resection of the rectum was performed. Postoperative adjuvant chemotherapy with 6 courses of oxaliplatin, Leucovorin, and 5-FU (FOLFOX4) and bevacizumab was initiated, followed by 5 courses of fluorouracil, Leucovorin, and irinotecan (FOLFIRI) and bevacizumab. Right posterior segment (S6, S7) hepatectomy with enucleation of S2, S3 and S5 was performed, and chemotherapy with FOLFOX4 (11 courses) was administered. New metastases in the S5 segment were observed in August 2011 and right hepatic lobectomy was performed. The patient then underwent 8 courses of adjuvant chemotherapy with FOLFOX4. However, left hepatic lobe lateral segment and caudate lobe metastases then appeared. Subsequent repeated chemotherapy with FOLFIRI plus cetuximab (3 courses) and irinotecan plus cetuximab was interrupted in August 2013 owing to adverse events resulting in rapid growth of hepatic metastases. The patient underwent hepatic left lateral segmentectomy and left caudate lobectomy. The postoperative course was uneventful and the patient has currently survived 4 years and 7 months after the initial surgery.
一名61岁男性于2009年12月被诊断为直肠癌伴多发肝转移,随后进行了直肠低位前切除术。术后开始进行6个疗程的奥沙利铂、亚叶酸钙和5-氟尿嘧啶(FOLFOX4)联合贝伐单抗的辅助化疗,之后进行了5个疗程的氟尿嘧啶、亚叶酸钙和伊立替康(FOLFIRI)联合贝伐单抗的化疗。进行了右后段(S6、S7)肝切除术,并摘除了S2、S3和S5,随后给予FOLFOX4化疗(11个疗程)。2011年8月观察到S5段出现新的转移灶,遂进行了右肝叶切除术。患者随后接受了8个疗程的FOLFOX4辅助化疗。然而,左肝叶外侧段和尾状叶出现转移。随后重复进行FOLFIRI联合西妥昔单抗化疗(3个疗程)以及伊立替康联合西妥昔单抗化疗,但在2013年8月因不良事件导致肝转移灶快速生长而中断。患者接受了左肝外侧段切除术和左尾状叶切除术。术后恢复顺利,患者目前已存活至初次手术后4年7个月。